The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Bonvalot, S., Rivoire, M., Castaing, M., Stoeckle, E., Le Cesne, A., Blay, J. Y., & Laplanche, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0802 · Cited by 644
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-303 · Cited by 581
Nagai, Y., Miyazawa, H., Huqun, Tanaka, T., Udagawa, K., Kato, M., Fukuyama, S., Yokote, A., Kobayashi, K., Kanazawa, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0331 · Cited by 504
Aparicio, A., & Chamberlain, M. C. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0081-7 · Cited by 487
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
Current Management of Brain Metastases, With a Focus on Systemic Options
Langer, C. J., & Mehta, M. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.145 · Cited by 368
Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · cited 1×
“Several cases in which intermittent, high-dose erlotinib improved CNS metastases that were resistant to continuous, normal-dose erlotinib have also been reported [6-9].”
BackgroundMukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg250 · Cited by 277
Gleissner, B., & Chamberlain, M. C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70443-4 · Cited by 277
Gerstner, E. R., & Fine, R. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.0677 · Cited by 265
Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jänne, P. A., & Johnson, B. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6126 · Cited by 260
Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 228
Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214 · cited 1×
“Several cases in which intermittent, high-dose erlotinib improved CNS metastases that were resistant to continuous, normal-dose erlotinib have also been reported [6-9].”
BackgroundZhang, R. D., Price, J. E., Fujimaki, T., Bucana, C. D., & Fidler, I. J. (1992) · PubMed Central · Cited by 186
Katayama, T., Shimizu, J., Suda, K., Onozato, R., Fukui, T., Ito, S., Hatooka, S., Sueda, T., Hida, T., Yatabe, Y., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b62572 · Cited by 159
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 154
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 133
Self-citationA critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors
Stewart, D. J. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052723 · Cited by 131
Weber, B., Winterdahl, M., Memon, A. A., Sørensen, B. S., Keiding, S., Sørensen, L. H., Nexø, E., & Meldgaard, P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318219ab87 · Cited by 131
Elmeliegy, M. A., Carcaboso, A. M., Tagen, M., Bai, F., & Stewart, C. F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1934 · Cited by 118
Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 107
Masuda, T., Hattori, N., Hamada, A., Iwamoto, H., Ohshimo, S., Kanehara, M., Ishikawa, N., Fujitaka, K., Haruta, Y., Murai, H., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1555-6 · Cited by 98
Yamamoto, N., Horiike, A., Fujisaka, Y., Murakami, H., Shimoyama, T., Yamada, Y., & Tamura, T. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0494-8 · Cited by 87
Togashi, Y., Masago, K., Fukudo, M., Tsuchido, Y., Okuda, C., Kim, Y. H., Ikemi, Y., Sakamori, Y., Mio, T., Katsura, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1691-z · Cited by 79
Self-citationZhao, M., He, P., Rudek, M. A., Hidalgo, M. M., & Baker, S. D. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00356-8 · Cited by 69
Carcinomatous Meningitis in Non–Small-Cell Lung Cancer: Response to High-Dose Erlotinib
Dhruva, N., & Socinski, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0963 · Cited by 64
Jones, H., Stafford, L. E., Swaisland, H., & Payne, R. K. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00014-6 · Cited by 63
Masters, A. R., Sweeney, C. J., & Jones, D. R. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.10.046 · Cited by 55
Hata, A., Kaji, R., Fujita, S., & Katakami, N. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d899bb · Cited by 50
Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic Approaches
Lombardi, G., Zustovich, F., Farina, P., Puppa, A. D., Manara, R., Cecchin, D., Brunello, A., Cappetta, A., & Zagonel, V. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0101 · Cited by 43
Fukuhara, T., Saijo, Y., Sakakibara, T., Inoue, A., Morikawa, N., Kanamori, M., Nakashima, I., & Nukiwa, T. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.214.359 · Cited by 37
Cited by
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Metadata
- Authors
- Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., & Mishima, M.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2012-07-18
- Volume
- 70
- Issue
- 3
- Pages
- 399-405
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2082148749
- Cited by
- 282
- References
- 37
- FWCI
- 13.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.